Insider Selling: Artivion, Inc. (NYSE:AORT) SVP Sells 18,020 Shares of Stock

Artivion, Inc. (NYSE:AORT) SVP Jean F. Holloway sold 18,020 shares of Artivion stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $23.61, for a total transaction of $425,452.20. Following the completion of the sale, the senior vice president now directly owns 197,184 shares of the company’s stock, valued at approximately $4,655,514.24. This trade represents a 8.37 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Artivion Stock Up 0.4 %

AORT opened at $23.58 on Thursday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88. Artivion, Inc. has a fifty-two week low of $19.11 and a fifty-two week high of $32.33. The firm’s fifty day moving average is $28.83 and its 200 day moving average is $27.77. The stock has a market cap of $991.37 million, a price-to-earnings ratio of -1,178.85 and a beta of 1.79.

Artivion (NYSE:AORT) last released its earnings results on Monday, February 24th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51). The firm had revenue of $97.31 million for the quarter, compared to analysts’ expectations of $100.82 million. Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. On average, sell-side analysts forecast that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on AORT shares. JMP Securities reaffirmed a “market outperform” rating and issued a $33.00 target price on shares of Artivion in a research report on Tuesday, December 10th. Stifel Nicolaus cut their price objective on shares of Artivion from $33.00 to $30.00 and set a “buy” rating for the company in a research report on Tuesday, February 25th. Finally, Needham & Company LLC lowered their target price on shares of Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday, February 25th. Five analysts have rated the stock with a buy rating, According to MarketBeat, Artivion presently has an average rating of “Buy” and an average target price of $31.40.

Institutional Trading of Artivion

Hedge funds have recently bought and sold shares of the stock. FMR LLC lifted its stake in Artivion by 28.0% in the 3rd quarter. FMR LLC now owns 115,184 shares of the company’s stock worth $3,066,000 after purchasing an additional 25,176 shares in the last quarter. Barclays PLC lifted its stake in Artivion by 346.3% in the 3rd quarter. Barclays PLC now owns 70,877 shares of the company’s stock worth $1,888,000 after purchasing an additional 54,996 shares in the last quarter. Lord Abbett & CO. LLC purchased a new stake in Artivion in the 3rd quarter worth $5,798,000. JPMorgan Chase & Co. lifted its stake in Artivion by 394.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 97,903 shares of the company’s stock worth $2,606,000 after purchasing an additional 78,120 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Artivion by 58.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company’s stock valued at $9,074,000 after buying an additional 125,668 shares in the last quarter. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.